Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687206 | 0.85 | SMN1; SMN2 (0.64) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL31520571 | 0.85 | SMN1; SMN2 (0.64) | CA1CA2MMP1MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL5344901 | 0.83 | SMN1; SMN2 (0.61) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29631615 | 0.78 | CA2 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL153130 | 0.75 | CA1 (0.67) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL151299 | 0.75 | CA1 (0.71) | CA1CA2CA9HTR6ALDH1A1 | |
| SCHEMBL29631718 | 0.75 | CA2 (0.76) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11245748 | 0.75 | SMN1; SMN2 (0.81) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29631569 | 0.74 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5284644 | 0.73 | CA1 (0.53) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002480-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc | 2025-01-02 | — | — | US | claimed |
| US-20250002480-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc | 2025-01-02 | — | — | US | disclosed |
| WO-2024243485-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-4436959-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118475562-A | Amino heteroaryl kinase inhibitors | 安锐生物医药公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240166635-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc | 2024-05-23 | — | — | US | disclosed |
| US-11919904-B2 | Sulfonylamide compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4251613-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023093769-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO.,LTD. (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| US-20200399273-A1 | SULFONYLAMIDE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919904-B2 | Sulfonylamide compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | CA1 2808/4885CA2 1355/4885MMP1 4256/4885 |
| US-20250002480-A1 | AMINOHETEROARYL KINASE INHIBITORS | CDK2, CDK3, CDKL1 | CA1 4266/4885CA2 4015/4885MMP1 3926/4885 |
| US-20200399273-A1 | SULFONYLAMIDE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CA1 2808/4885CA2 1355/4885MMP1 4256/4885 |
| US-20240166635-A1 | AMINOHETEROARYL KINASE INHIBITORS | CDK2, CDK3, CDKL1 | CA1 4314/4885CA2 3798/4885MMP1 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.